Why the study?
Does valsartan added to background therapy reduce plasma aldosterone in patients with chronic heart failure?
Does valsartan added to background therapy reduce plasma aldosterone in patients with chronic heart failure?
Valsartan reduces plasma aldosterone in heart failure, but aldosterone levels may not reliably mark disease progression.
Valsartan lowers aldosterone in chronic HF without consistent outcome linkage; challenges its role as a progression marker and supports outcome-focused trials.
Valsartan added to background therapy for heart failure produces sustained reduction in plasma aldosterone, consistent with the observed significant reduction in the combined mortality/morbidity end point. A similar reduction in all subgroups based on ACE-I or BB therapy, despite differing clinical outcomes in these subgroups, suggests that aldosterone plasma levels may not be a critical marker of the progression of heart failure.
No takes yet. Share an insight, caveat, or question.
Cohn et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: